Startseite>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>2-Aminoimidazole

2-Aminoimidazole

Katalog-Nr.GC61639

2-Aminoimidazol ist ein wirksames Antibiofilm-Mittel, das als Adjuvans fÜr antimikrobielle Mittel verwendet werden kann.

Products are for research use only. Not for human use. We do not sell to patients.

2-Aminoimidazole Chemische Struktur

Cas No.: 7720-39-0

Größe Preis Lagerbestand Menge
250 mg
46,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

2-Aminoimidazole is a potent antibiofilm agent that can be used as an adjuvant to antimicrobial. 2-aminoimidazoles disrupts the ability of bacteria to protect themselves by inhibiting biofilm formation and genetically-encoded antibiotic resistance traits. 2-Aminoimidazole is also a weak noncompetitive inhibitor of human arginase I with a Ki of 3.6 mM[1][2][3].

[1]. Thompson RJ, et, al. Identification of BfmR, a response regulator involved in biofilm development, as a target for a 2-Aminoimidazole-based antibiofilm agent. Biochemistry. 2012 Dec 11;51(49):9776-8. [2]. Jacobs L, et, al. 2-Aminoimidazoles as potent inhibitors of contaminating brewery biofilms. Biofouling. 2021 Feb 11;1-17. [3]. Ilies M, et, al. 2-aminoimidazole amino acids as inhibitors of the binuclear manganese metalloenzyme human arginase I. J Med Chem. 2010 May 27;53(10):4266-76.

Bewertungen

Review for 2-Aminoimidazole

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 2-Aminoimidazole

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.